Testing NWRD09 for persistent HPV16 infection in women
Part of Cancer, Infections, Women’s health & pregnancy clinical trials.
This study tests a new treatment called NWRD09 for women with a long-lasting HPV16 infection that shows concerning cell changes in the cervix. The goal is to see if this treatment can help your immune system clear the infection and prevent it from developing into cervical cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female, between 18 and 60 years old
- You have had HPV16 virus detected in your body for at least 6 months, including at the screening visit
- Your cervical cells show abnormal changes (ASC-H or HSIL) on a Pap test or biopsy
- Your colposcopy (close examination of the cervix) at screening looks normal
- You do not have HIV, hepatitis B, hepatitis C, or other serious infections
- You are willing to use effective birth control throughout the study and not donate eggs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (NWRD09) for people who have had HPV type 16 infection in the anal area for over a year. It aims to see if the drug can help clear the virus without causing serious side effects.
This Phase 1/2 trial tests a one-time infusion of special immune T cells made to recognize your HPV16 tumor. It may help your body attack the cancer, while researchers closely monitor safety and early effectiveness.
This trial tests an experimental treatment called NWRD09 for women who have had a persistent HPV 16 infection for at least 12 months. The goal is to see if it can clear the virus and prevent cervical changes.
This trial tests a new medicine called NWRD09 for people with HPV-16 related cervical cell changes (HSIL) or advanced cervical cancer. The goal is to see if it can help treat these conditions.
This trial tests a new drug called NWRD09 for women with a high-grade precancerous cervical condition caused by HPV type 16. If you qualify, you would receive the study drug and be monitored to see if it can help clear the abnormal cells.
This trial tests a new vaccine called NWRD09 for women with HPV-16-related changes in the cervix, vagina, or vulva (precancer) or with advanced cervical cancer that has come back or spread. It aims to see if the vaccine can help the body fight the HPV infection and related disease.
Hear when a new Persistent HPV16 Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.